Table 5.
Local recurrence overall recurrence and survival after scheduled second TACE stratified by BCLC stage
| Subgroup | Local recurrence free survival rate (%) at 1 year | Adjusted* HR (95% CI) | P-value | Overall recurrence free survival rate (%) at 1 years | Adjusted* HR (95% CI) | P-value | Overall survival rate (%) at 5 years | Adjusted* HR (95% CI) | P-value |
|---|---|---|---|---|---|---|---|---|---|
| BCLC 0 (n=51) | 69.0 vs. 84.6 | 1.48 (0.68-3.20) | 0.31 | 58.6 vs. 42.1 | 0.90 (0.46-1.77) | 0.77 | 76.0 vs. 85.6 | 0.82 (0.21-3.11) | 0.77 |
| BCLC A (n=127) | 44.7 vs. 50.6 | 0.60 (0.38-0.95) | 0.029 | 42.1 vs. 32.7 | 1.04 (0.68-1.59) | 0.84 | 39.1 vs. 62.1 | 0.58 (0.34-0.98) | 0.034 |
TACE, transarterial chemoembolization; BCLC, Barcelona clinic liver cancer; HR, hazard ratio; CI, confidence interval.
*
Adjusted for tumor number, size and Child-Pugh score.